EntryPoint Capital LLC Increases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

EntryPoint Capital LLC grew its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 126.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 55,539 shares of the company’s stock after buying an additional 31,020 shares during the quarter. EntryPoint Capital LLC’s holdings in 4D Molecular Therapeutics were worth $309,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new position in shares of 4D Molecular Therapeutics in the 4th quarter worth about $48,000. PNC Financial Services Group Inc. boosted its position in shares of 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after purchasing an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in shares of 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after buying an additional 9,737 shares during the last quarter. Fox Run Management L.L.C. bought a new position in 4D Molecular Therapeutics during the 4th quarter valued at approximately $69,000. Finally, AlphaQuest LLC raised its stake in 4D Molecular Therapeutics by 3,665.2% during the fourth quarter. AlphaQuest LLC now owns 14,835 shares of the company’s stock valued at $83,000 after buying an additional 14,441 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Price Performance

NASDAQ FDMT opened at $3.56 on Friday. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.50 and a 1-year high of $34.20. The stock has a market capitalization of $164.84 million, a price-to-earnings ratio of -1.25 and a beta of 2.83. The business’s fifty day moving average price is $4.60 and its 200-day moving average price is $7.17.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). Equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Bank of America cut their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Leerink Partners dropped their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Finally, Chardan Capital decreased their price objective on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.63.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.